Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy

Epilepsy Drug Epidiolex Adds To Sleep, Oncology Franchises

Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.

Merging, two merchants push the red squares and other squares together
Sales of Epidiolex last year equal almost a quarter of Jazz's expected 2020 revenue • Source: Shutterstock

Jazz Pharmaceuticals plc revealed on 3 February that it is paying a big premium to add the high-growth rare epilepsy drug Epidiolex (cannabidiol) to its commercial portfolio and additional cannabinoid therapeutics to its pipeline with the $7.2bn purchase of GW Pharmaceuticals plc. The cash and stock transaction values GW Pharma at $220 per American depository share (ADS), which is 50% more than the London-based firm’s 2 February closing ADS price of $146.25.

During an investor call, Jazz chairman and CEO Bruce Cozadd declined to disclose whether the purchase price for GW reflects...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.